Merck ups FY earnings view; Q2 beats estimates

29 July 2015
biosimilars_samples_large

US pharma giant Merck & Co (NYSE: MRK) on Tuesday raised its outlook for full-year profit while posting a second-quarter earnings ahead of estimates despite a drop in sales.

The company reported second-quarter earnings down over 65% at $687 million, or $0.24 a share, against $2 billion, or $0.68 a share a year earlier. Overall, sales dropped 11% to $9.79 billion.

The drugmaker raised its full-year adjusted earnings target to $3.45 to $3.55 a share, from $3.35 to $3.48 a share.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars